The News
Omthera Pharmaceuticals announces Positive Long Term Bioavailability data comparing Epanova™ to Lovaza®
10/01/2012
Epanova Increased EPA And DHA More than 5‐Fold Compared to Lovaza After 2 Weeks of Dosing in 52 Subjects on A Low Fat Diet: Preliminary Data To Be Presented at J.P. Morgan Healthcare Conference In San Francisco On January 10, 2012.
...
2012
-
10/01/2012
Omthera Pharmaceuticals announces Positive Long Term Bioavailability data comparing Epanova™ to Lovaza®
-
22/02/2012
BioAmber Closes $30 Million Financing with LANXESS and Existing Investors
- 22/02/2012
- 17/02/2012
- 17/02/2012
- 14/02/2012
- 28/02/2012
- 28/02/2012
- 21/03/2012
-
22/03/2012
Avantium and Danone sign development partnership for Next Generation bio-based plastic: PEF
-
26/03/2012
STENTYS Self-Apposing™ technology supported by breaking new scientific evidence
- 29/03/2012
-
29/03/2012
Sofinnova Partners annonce le succès de l'introduction en bourse de DBV Technologies qui lève 40,5M€
-
02/04/2012
Ablynx receives milestone payment as collaborator receives IND approval for a nanobody in oncology
-
04/04/2012
NOXXON's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model
- 04/04/2012
- 12/04/2012
- 25/04/2012
-
26/04/2012
Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
- 12/05/2012
-
15/05/2012
First quarter 2012 topline, scientific activity and upcoming clinical data
-
10/05/2012
DBV Technologies welcomes Charles Ruban as Chief Development Officer
- 10/05/2012
-
15/05/2012
Chiffre d’affaires du 1er trimestre, activité scientifique et données cliniques à venir
